.webp?width=217&height=60&name=Screenpoint-Med%20(1).webp "Screen Point Medical")
.png?width=600&height=600&name=SBI_1%20(1).png)
Attending SBI 2026?
Join us for the largest gathering of breast imaging experts worldwide from April 16-19 in Seattle
.png?width=60&height=60&name=connect_1%20(1).png)
Our focus is to continuously evolve Breast AI with innovative new products and enhanced algorithms
.png?width=60&height=60&name=book_1%20(1).png)
The most independent peer-reviewed publications in Breast AI; part of three randomised controlled trials
.png?width=60&height=60&name=shield_1%20(1).png)
FDA cleared and CE marked for 2D and 3D mammography; vendor agnostic solutions work with your technology
.png?width=600&height=600&name=rad_1%20(1).png)
.svg)
Improved workflow
regardless of acquisition type (FFDM, DBT) or reading environment (single reading, double reading), Transpara works where and how you do
.svg)
Greater confidence
Transpara excels across variables: age and breast density, radiologist experience level, ethnicity, and more. Trusted in 30+ countries
Enhanced detection
in published results from a randomised controlled trial in Breast AI, Transpara increased cancer detection by 29% and reduced workload 44%
One of the great strengths of Transpara is the high negative predictive value of Low Risk results. When a finding is classified as Low Risk, we can have a high degree of confidence that the exam is negative. This has been confirmed both in the published scientific literature and through our own internal audit across our population.
Transpara increases my confidence and efficiency going through a screening mammography session. I have more focus especially with the higher risk cases thanks to their intuitive triage software.
We are now prospectively implementing Transpara in our screening program and we are very excited to see the results from our prospective trial. Even better, we have observed that the latest version of Transpara has significantly improved the detection performance of the system, and a higher sensitivity is achieved at high specificity.
Transpara has the potential to detect specific cancers earlier. I can think of 1-2 recent cases with calcifications, where Transpara detected a cancer earlier that was not easily visible on a mammogram.
We are at the forefront of one of the first prospective studies with Transpara. As we will implement Transpara in a real-life screening setting in Ostergotland County, we aim to improve the quality of the breast cancer screening program while at the same time safely reduce the workload of breast radiologists.
Transpara may allow discriminating studies, which require more attention and selection of those, which may be handled with single reading for example. It may thus contribute significantly to both risk adapted screening and optimum assignment of resources.
I use Transpara all the time, and won’t read another 3D mammogram without it. The product fits seamlessly into our workflow, and we have found over time it has increased our mammography workflow. Thanks to the technology’s score card we are also able to focus on those high risk patients first, and get those patients the care they may need faster.
MASAI RCT: 12% reduction in interval cancer rate using Transpara
%20(1).png)
MASAI RCT: 12% reduction in interval cancer rate using Transpara
January 30, 2026
What studies showed us about Transpara in 2025
What studies showed us about Transpara in 2025
December 22, 2025
Transpara® Breast AI Selected for $16M PRISM Randomized Controlled Trial in USA
.png)
Transpara® Breast AI Selected for $16M PRISM Randomized Controlled Trial in USA
September 23, 2025